🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM ISL/LEN, ISLATRAVIR/LENACAPAVIR, ISLATRAVIR/LENACAPAVIR, PTM Biktarvy

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  2. Bimatoprost SR

    AbbVie Deutschland GmbH & Co. KG

    Open-angle Glaucoma, Ocular Hypertension

    phase 3 small molecule active

    1 trial

  3. Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 320 mg solution for injection in pre-filled pen, Placebo matching test. 0.9% sodium chloride solution for injection (unauthorized)., Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Palmoplantar Pustulosis

    phase 3 small molecule active

    1 trial

  4. Biological Therapies Sodium Ascorbate Solution 30 g in 100 mL Injection, SODIUM CHLORIDE

    Pari Pharma GmbH

    Patient with sepsis complicated by ARDS

    phase 3 small molecule active

    1 trial

  5. Biological/Vaccine

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 3 mab active

    1 trial

  6. Bion 1301/FUB523

    Novartis Pharmaceuticals

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  7. Biosteron, 10 mg, tabletki, Senaxa PR, 2 mg, tabletki o przedłużonym uwalnianiu

    Lacuna Pharma Pty Ltd

    Menopause, sleep disorders in the postmenopausal period

    phase 3 small molecule active

    1 trial

  8. Bitopertin

    Disc Medicine

    X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyria (EPP)

    phase 3 small molecule active

    1 trial

  9. Bitopertin, Matching Placebo

    Disc Medicine

    X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyria (EPP)

    phase 3 small molecule active

    1 trial

  10. Bortezomib STADA 2,5 mg/ml Injektionslösung, Dexamethason 0,5 mg JENAPHARM®, Empliciti 400 mg powder for concentrate for solution for infusion., Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, -, Nodexon 20 mg tabletes, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Nodexon 20 mg tabletės, ELRANATAMAB, Dexamethason 4 mg JENAPHARM®

    Pfizer Australia Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. Bosulif 500 mg film-coated tablets, Olverembatinib, Bosulif 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  12. Budesonida Aldo-Unión 0,5 mg/ml suspensión para inhalación por nebulizador, CUROSURF® 120mg/vial + 240mg/vial Endotracheopulmonary Instillation Suspension

    The George Institute

    Bronchopulmonary dysplasia, Preterm newborns ≤32 weeks of gestational age.

    phase 3 small molecule active

    1 trial

  13. C1 esterase inhibitor [human] (C1INH-nf)

    Takeda

    Hereditary Angioedema

    phase 3 mab completed

    5 trials

  14. C1 esterase inhibitor [human] liquid

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  15. CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, PLACEBO, CASDATIFAN

    Arcus Biosciences

    Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  16. CALCIUM FOLINATE, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BEVACIZUMAB, BEVACIZUMAB, PANITUMUMAB, SOTORASIB, FLUOROURACIL

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  17. CALCIUM FOLINATE, OPDIVO 10 mg/mL concentrate for solution for infusion., BNT327 20 mg ml, OXALIPLATIN, FLUOROURACIL, BNT327 50 mg ml, CAPECITABINE, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  18. CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot)

    Camurus Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  19. CAM2029 (octreotide subcutaneous depot), SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Somatuline Autogel 120 mg, solution for injection in a pre-filled syringe

    Camurus Pty Ltd

    gastroenteropancreatic neuroendocrine tumors

    phase 3 small molecule active

    1 trial

  20. CANAKINUMAB, PEMETREXED

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  21. CAPECITABINE

    Disc Medicine

    Salivary Duct Carcinoma

    phase 3 small molecule active

    1 trial

  22. CAPECITABINE , METFORMIN , ACETYLSALICYLIC ACID , OXALIPLATIN

    Fondazione Telethon ETS

    Locally advanced stage II/III rectal cancer

    phase 3 small molecule active

    1 trial

  23. CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    AstraZeneca AB

    Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  24. CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB

    AstraZeneca AB

    HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources